...
首页> 外文期刊>Early human development >Hematological morbidity and management in neonates with hemolytic disease due to red cell alloimmunization.
【24h】

Hematological morbidity and management in neonates with hemolytic disease due to red cell alloimmunization.

机译:红细胞同种免疫引起的溶血病新生儿的血液学发病率和管理。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Treatment of severe anemia with intrauterine red cell transfusions in fetuses with red cell alloimmunization has led to a dramatic increase in perinatal survival. Due to this increased survival focus is nowadays shifting towards improving postnatal treatment options. Phototherapy, exchange transfusions and intravenous immunoglobulin are used to treat hyperbilirubinemia and prevent kernicterus. Postnatal treatment of anemia consists of top-up transfusions, supplements to support erythropoiesis such as folic acid and iron, and occasionally erythropoietin treatment. In addition to anemia, other hematological complications such as thrombocytopenia, coagulation disturbances, leucopenia and iron overload have been reported. This review focuses on the hematological morbidity in neonates with red cell alloimmunization and summarizes the current evidence on management options.
机译:通过红细胞同种免疫在胎儿中进行宫内红细胞输注治疗严重贫血,导致围产期生存期显着增加。由于这种增加的生存率,如今的重点是转向改善产后治疗选择。光疗,交换输血和静脉注射免疫球蛋白可用于治疗高胆红素血症和预防角膜溃疡。贫血的产后治疗包括充血,叶酸和铁等支持促红细胞生成的补充剂以及偶尔的促红细胞生成素治疗。除贫血外,还报告了其他血液学并发症,例如血小板减少症,凝血障碍,白细胞减少症和铁超负荷。这篇综述着重于红细胞同种免疫的新生儿血液学发病率,并总结了当前有关治疗选择的证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号